2022. Incidence and factors associated with adverse drug reactions in a cohort of individuals starting dolutegravir or efavirenz . Research, Society and Development. 11, 4 (Mar. 2022), e0811426250. DOI:https://doi.org/10.33448/rsd-v11i4.26250.